Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers.
Author(s): Hilpert J, Beekman JM, Schwenke S, Kowal K, Bauer D, Lampe J, Sandbrink R, Heubach JF, Sturzebecher S, Reischl J
Affiliation(s): Clinical Pharmacology, Bayer Schering Pharma AG, Berlin, Germany.
Publication date & source: 2008-08-13, J Neuroimmunol., 199(1-2):115-25. Epub 2008 Jun 18.
Treatment with interferon beta-1b (IFNB-1b) is clinically effective in multiple sclerosis patients. However, the mechanism of action is only partially understood, and validated biological response markers are lacking. We assessed IFNB-1b-induced transcriptional changes by microarray technology. Healthy male volunteers received 250 mug IFNB-1b or placebo in a double-blind, randomized controlled trial (n=5 per group). Most transcripts demonstrated peak levels after 6-12 h and returned to baseline after 48 h. We identified 227 differentially regulated genes including novel and previously described markers. This panel may become a valuable tool for development of new IFNB-1b formulations and assessment of clinical drug effects.
|